Patents by Inventor Dan Michael Weinthal

Dan Michael Weinthal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250032542
    Abstract: The present disclosure relates to powerful trans immune-modulatory systems, compositions and methods based on targeted genetic modification of immune-regulatory genes, for modulating immune cells and treating immune-related disorders. The disclosed systems comprise at least one donor nucleic acid molecule that encodes a replacement sequence that specifically integrates in a target sequence within a first immunoregulatory gene. The disclosed system further comprises at least one target recognition element, that targets the donor molecule to the target first immune-modulatory gene. The integration in the first target gene results in the production of at least one immune-modulatory product and/or modulation of the expression and/or activity of the immune-regulatory gene and any product thereof.
    Type: Application
    Filed: November 10, 2022
    Publication date: January 30, 2025
    Inventors: Dan Michael WEINTHAL, Yoel Moshe SHIBOLETH, David STEINER, Talya KUNIK
  • Publication number: 20240374758
    Abstract: The present disclosure provides nucleic acid guided genome modifier chimeric or fusion proteins, complexes or conjugate thereof, having enhanced homology-directed repair (HDR). The nucleic acid guided genome modifier disclosed herein comprise the following two components (a) at least one defective CRISPR-Cas protein (CRISPR-dCas) devoid of a nucleolytic activity or any variant or mutant thereof; and (b) at least one nucleic acid modifier component; and at least one of: (c) at least one donor attachment domain (DAD) for binding at least one Donor nucleic acid molecule; and (d) at least one repair factor recruitment domain (RFRD). The present disclosure further provides nucleic acid sequences encoding the nucleic acid guided genome modifier disclosed herein, as well as systems thereof and therapeutic and non-therapeutic methods thereof.
    Type: Application
    Filed: August 15, 2022
    Publication date: November 14, 2024
    Inventors: Dan Michael WEINTHAL, Yoel Moshe SHIBOLETH, Talya KUNIK, Devin Lee TRUDEAU
  • Publication number: 20240148771
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: May 15, 2023
    Publication date: May 9, 2024
    Applicant: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • Publication number: 20230220425
    Abstract: The invention provides highly effective and versatile CRISPR/Cas protein variants, compositions, methods and uses thereof in gene editing. More specifically, the invention relates to PAM-reduced or PAM-abolished Cas proteins and chimeras, complexes and conjugates thereof, genetic editing systems and to therapeutic and non-therapeutic methods and uses of the PAM-reduced or PAM-abolished Cas proteins.
    Type: Application
    Filed: October 28, 2020
    Publication date: July 13, 2023
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL, Devin Lee TRUDEAU, Talya KUNIK, Mati COHEN
  • Patent number: 11690866
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: July 4, 2023
    Assignee: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Patent number: 11458157
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: December 16, 2012
    Date of Patent: October 4, 2022
    Assignee: Targetgene Biotechnologies Ltd.
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Patent number: 11278560
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 22, 2022
    Assignee: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Patent number: 10220052
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: March 5, 2019
    Assignee: TARGETGENE BIOTECHNOLOGIES LTD
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Publication number: 20170319613
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: March 3, 2017
    Publication date: November 9, 2017
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • Publication number: 20170233752
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Applicant: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • Publication number: 20170183687
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 29, 2017
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • Publication number: 20150211023
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: December 16, 2012
    Publication date: July 30, 2015
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal